Guggenheim Capital LLC Ionis Pharmaceuticals Inc Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 37,159 shares of IONS stock, worth $1.31 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

37,159

Previous 35,389 5.0%

Holding current value

$1.31 Million

Previous $1.69 Million 11.74%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$40.06 - $51.86 $70,906 - $91,792	1,770 Added 5.0%	37,159 $1.49 Million
Q2 2024 Aug 14, 2024	SELL	$36.45 - $47.7 $16,803 - $21,989	-461 Reduced 1.29%	35,389 $1.69 Million
Q1 2024 May 14, 2024	BUY	$42.03 - $53.55 $113,438 - $144,531	2,699 Added 8.14%	35,850 $1.55 Million
Q4 2023 Feb 14, 2024	SELL	$43.39 - $51.63 $317,788 - $378,138	-7,324 Reduced 18.1%	33,151 $1.68 Million
Q3 2023 Nov 14, 2023	SELL	$38.5 - $47.13 $440,863 - $539,685	-11,451 Reduced 22.05%	40,475 $1.84 Million
Q2 2023 Aug 11, 2023	SELL	$34.73 - $43.33 $404,153 - $504,231	-11,637 Reduced 18.31%	51,926 $2.13 Million
Q1 2023 May 10, 2023	BUY	$33.58 - $41.2 $47,146 - $57,844	1,404 Added 2.26%	63,563 $2.27 Million
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $266,892 - $334,478	7,190 Added 13.08%	62,159 $2.35 Million
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $320,711 - $427,088	-8,777 Reduced 13.77%	54,969 $2.43 Million
Q2 2022 Aug 15, 2022	SELL	$31.71 - $43.0 $142,409 - $193,113	-4,491 Reduced 6.58%	63,746 $2.36 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $141,661 - $175,606	-4,741 Reduced 6.5%	68,237 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $35.1 $264,833 - $362,969	10,341 Added 16.51%	72,978 $2.22 Million
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $218,043 - $263,615	6,501 Added 11.58%	62,637 $2.1 Million
Q2 2021 Aug 13, 2021	SELL	$34.54 - $47.25 $526,942 - $720,846	-15,256 Reduced 21.37%	56,136 $2.24 Million
Q1 2021 May 13, 2021	BUY	$42.51 - $63.78 $447,970 - $672,113	10,538 Added 17.32%	71,392 $3.21 Million
Q4 2020 Feb 16, 2021	SELL	$45.3 - $60.27 $605,525 - $805,629	-13,367 Reduced 18.01%	60,854 $3.44 Million
Q3 2020 Nov 13, 2020	SELL	$47.45 - $62.95 $218,981 - $290,514	-4,615 Reduced 5.85%	74,221 $3.52 Million
Q2 2020 Aug 14, 2020	BUY	$46.85 - $61.05 $606,520 - $790,353	12,946 Added 19.65%	78,836 $4.65 Million
Q1 2020 Jun 02, 2020	SELL	$41.6 - $63.4 $602,243 - $917,841	-14,477 Reduced 18.01%	65,890 $3.12 Million
Q4 2019 Feb 14, 2020	BUY	$53.85 - $65.27 $701,396 - $850,141	13,025 Added 19.34%	80,367 $4.86 Million
Q3 2019 Nov 14, 2019	SELL	$59.06 - $72.15 $204,761 - $250,144	-3,467 Reduced 4.9%	67,342 $4.03 Million
Q2 2019 Aug 14, 2019	SELL	$62.09 - $86.14 $120,268 - $166,853	-1,937 Reduced 2.66%	70,809 $4.55 Million
Q1 2019 May 15, 2019	SELL	$52.92 - $81.17 $586,988 - $900,337	-11,092 Reduced 13.23%	72,746 $5.91 Million
Q4 2018 Feb 14, 2019	SELL	$43.37 - $59.54 $541,214 - $742,999	-12,479 Reduced 12.96%	83,838 $4.53 Million
Q3 2018 Nov 14, 2018	BUY	$42.88 - $53.7 $23,584 - $29,535	550 Added 0.57%	96,317 $4.97 Million
Q2 2018 Aug 14, 2018	BUY	$40.53 - $50.7 $181,777 - $227,389	4,485 Added 4.91%	95,767 $3.99 Million
Q1 2018 May 15, 2018	BUY	$44.08 - $55.05 $83,443 - $104,209	1,893 Added 2.12%	91,282 $4.02 Million
Q4 2017 Feb 14, 2018	SELL	$50.3 - $64.39 $672,309 - $860,636	-13,366 Reduced 13.01%	89,389 $4.5 Million
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $4.68 Million - $6.12 Million	102,755	102,755 $5.21 Million

Others Institutions Holding IONS

# of Institutions

404

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.02B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Ionis Pharmaceuticals Inc Transaction History